Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2017 /
Long term efficacy of denosumab for giant cell bone tumours

8th - 12th Sep 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.09.17
Views: 1099

Prof Emanuela Palmerini - Rizzoli Orthopedic Institute, Bologna, Italy

Prof Palmerini speaks with ecancer at ESMO 2017 about a phase II trial of denosumab in over 500 patients with giant cell bone cancer, who were treated for up to 8 years.

She describes the significant improvements in patient recovery and quality of life compared to surgical interventions, with even the 34% of patients who relapsed responding to subsequent denosumab, and the suitability of denosumab following surgery.

Prof Palmerini describes the toxicity profile as manageable, noting early intervention with any osteonecrosis of the jaw as the best course of action, and recommends denosumab for most eligible patients.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence